Oncotelic Therapeutics Inc. has unveiled new data demonstrating its Deciparticle platform can reliably formulate diverse hydrophobic drugs into uniform, intravenous-ready nanoparticles. The platform shows particular promise with Everolimus (Afinitor), where preclinical pharmacokinetic data reveal the intravenous formulation, designated Sapu003, reduces gastrointestinal drug accumulation by up to 67-fold compared to oral dosing.
This advancement represents a significant step in next-generation drug delivery for immunology and oncology treatments. The company presented this data at the 2025 San Antonio Breast Cancer Symposium, highlighting how its nanotechnology can package water-resistant drugs into smaller, uniform nanoparticles suitable for safe intravenous administration. The platform's ability to transform oral medications into intravenous formulations could address significant treatment limitations in cancer care.
The Deciparticle platform demonstrates broad compatibility across multiple therapeutic categories. Research shows it successfully forms stable, monodisperse particles with all five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus, and umirolimus. The platform also works effectively with tacrolimus, another key therapeutic agent. This versatility suggests the technology could be applied to numerous existing drugs that currently face delivery challenges due to their hydrophobic nature.
For business leaders and technology executives monitoring the biotechnology sector, Oncotelic's developments signal a shift toward more modular, scalable nanomedicine engineering. The company's platform is described as cGMP-ready, indicating it meets current Good Manufacturing Practice standards required for pharmaceutical production. This positions Oncotelic as an emerging player in drug delivery innovation with potential applications across multiple therapeutic areas.
The implications for the pharmaceutical industry are substantial. By converting oral medications to intravenous formulations with reduced gastrointestinal accumulation, the technology could improve patient outcomes through more precise drug delivery and potentially reduced side effects. The platform's ability to work with multiple drug classes suggests it could become a foundational technology for reformulating existing therapeutics, extending patent protection, and creating new treatment options without requiring entirely new drug discovery.
Additional information about Oncotelic Therapeutics is available through the company's newsroom at https://ibn.fm/OTLC. The original data presentation from the San Antonio Breast Cancer Symposium can be accessed at https://ibn.fm/LxQ7N. These developments in nanomedicine engineering represent a convergence of biotechnology innovation and scalable manufacturing approaches that could transform how challenging therapeutic agents are delivered to patients.
